Literature DB >> 15761022

Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.

Hong Chang1, A Keith Stewart, Xiao Ying Qi, Zhi Hua Li, Qi Long Yi, Suzanne Trudel.   

Abstract

The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). Because t(4;14) uniquely results in fibroblast growth factor receptor 3 (FGFR3) expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3, and its expression was correlated with the t(4;14) status. FISH detected t(4;14) in 16 (19%) of 85 MM patient specimens, and immunocytochemistry detected aberrant FGFR3 expression in 13 (15%). Twelve (75%) t(4;14)-positive cases expressed FGFR3, and 12 (92%) FGFR3-positive cases harbored a t(4;14). FGFR3 expression and t(4;14) were strongly correlated (P < .001). FGFR3 expression by immunohistochemistry was associated with the immunoglobulin A (IgA) isotype (P < .001), a shorter progression-free survival (median, 11.5 versus 25.8 months; P < .001), and a shorter overall survival (median, 19.2 versus 46.3 months; P < .001).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761022     DOI: 10.1182/blood-2005-01-0033

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.

Authors:  A K Stewart; H Chang; S Trudel; K C Anderson; P Richardson; M Alsina; D Reece; S Young; A Sable-Hunt; Z Li; J Keats; S Van Wier; G Ahmann; T Price-Troska; K Giusti; P L Bergsagel; M Chesi; R Fonseca
Journal:  Leukemia       Date:  2007-06-14       Impact factor: 11.528

Review 2.  Novel therapies in MM: from the aspect of preclinical studies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2011-09-01       Impact factor: 2.490

Review 3.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

4.  CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.

Authors:  Hong Chang; Nan Jiang; Hua Jiang; Manujendra N Saha; Connie Qi; Wei Xu; Donna Reece
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

5.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Authors:  Brittany C Parker; Matti J Annala; David E Cogdell; Kirsi J Granberg; Yan Sun; Ping Ji; Xia Li; Joy Gumin; Hong Zheng; Limei Hu; Olli Yli-Harja; Hannu Haapasalo; Tapio Visakorpi; Xiuping Liu; Chang-Gong Liu; Raymond Sawaya; Gregory N Fuller; Kexin Chen; Frederick F Lang; Matti Nykter; Wei Zhang
Journal:  J Clin Invest       Date:  2013-01-09       Impact factor: 14.808

6.  Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.

Authors:  Norihiro Kotani; Yoshihito Ishiura; Ryusuke Yamashita; Tomoko Ohnishi; Koichi Honke
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

Review 7.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 8.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 9.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

10.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Authors:  Jing Qing; Xiangnan Du; Yongmei Chen; Pamela Chan; Hao Li; Ping Wu; Scot Marsters; Scott Stawicki; Janet Tien; Klara Totpal; Sarajane Ross; Susanna Stinson; David Dornan; Dorothy French; Qian-Rena Wang; Jean-Philippe Stephan; Yan Wu; Christian Wiesmann; Avi Ashkenazi
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.